TrialJAMA oncology2018

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Dickran Kazandjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.